#1 Clinical Trials Search in Europe

Epirubicin

This article explores the use of epirubicin, a chemotherapy drug, in various clinical trials for cancer treatment. Epirubicin is being studied in different types of cancer, dosing regimens, and combinations with other drugs to evaluate its efficacy and safety. The trials aim to improve treatment outcomes and reduce side effects for cancer patients.

Table of Contents

What is Epirubicin?

Epirubicin is a chemotherapy medication used in the treatment of various types of cancer. It belongs to a class of drugs called anthracyclines, which are known for their ability to interfere with cancer cell growth and division[1]. Epirubicin is also known by its brand name Ellence[2].

What Conditions Does Epirubicin Treat?

Epirubicin is primarily used to treat the following conditions:

  • Breast Cancer: It is commonly used in the treatment of various stages of breast cancer, including early-stage and advanced breast cancer[1][3].
  • Gastric (Stomach) Cancer: Epirubicin is used in combination with other drugs to treat locally advanced gastric cancer[4].
  • Bladder Cancer: It is used in the treatment of non-muscle invasive bladder cancer (NMIBC)[5].

How Does Epirubicin Work?

Epirubicin works by damaging the DNA of cancer cells, which prevents them from growing and dividing. It is considered a DNA damaging drug[6]. By interfering with the cancer cells’ ability to replicate, epirubicin helps to slow down or stop the growth of tumors.

How is Epirubicin Administered?

Epirubicin is typically administered in the following ways:

  • Intravenous (IV) Infusion: The most common method is through an IV infusion, where the drug is given directly into a vein over a period of time, usually 15-30 minutes[1].
  • Intravesical Instillation: For bladder cancer, epirubicin may be administered directly into the bladder through a catheter. This method is called intravesical instillation[5].

Dosage and Treatment Regimens

The dosage and treatment schedule for epirubicin can vary depending on the type of cancer being treated, the stage of the disease, and other individual factors. Some common regimens include:

  • Breast Cancer: Doses typically range from 75-100 mg/m² given every 3 weeks as part of a combination chemotherapy regimen[2].
  • Gastric Cancer: A common dose is 50 mg/m² given every 3 weeks in combination with other chemotherapy drugs[4].
  • Bladder Cancer: For intravesical use, a typical dose is 50 mg in 50 ml of saline solution, instilled into the bladder and retained for 1 hour[5].

It’s important to note that these are general guidelines, and your doctor will determine the most appropriate dosage and schedule for your specific situation.

Side Effects and Safety Considerations

Like all chemotherapy drugs, epirubicin can cause side effects. Some common side effects include:

  • Nausea and vomiting
  • Hair loss (alopecia)
  • Fatigue
  • Decreased blood cell counts, which can increase the risk of infection, anemia, and bleeding
  • Mouth sores
  • Skin and nail changes

One important safety consideration is the potential for heart problems. Epirubicin can affect heart function, especially at higher cumulative doses. Your doctor will monitor your heart health throughout treatment[7].

Ongoing Research and Clinical Trials

Researchers are continually studying epirubicin to improve its effectiveness and safety. Some areas of ongoing research include:

  • Genetic-based dosing: Studies are exploring whether adjusting epirubicin doses based on a patient’s genetic profile can improve outcomes and reduce side effects[3].
  • Combination therapies: Researchers are investigating the effectiveness of combining epirubicin with other drugs, such as vinorelbine, for treating advanced breast cancer[6].
  • New applications: Surprisingly, a clinical trial is exploring the use of very low doses of epirubicin for treating sepsis, a severe systemic infection. This is based on animal studies showing that low-dose epirubicin might help the body tolerate infections better[7].

These ongoing studies aim to improve the way epirubicin is used, potentially leading to better outcomes and fewer side effects for patients in the future.

Aspect Details
Cancer Types Studied Breast cancer, bladder cancer, sepsis
Administration Methods Intravenous (IV), various dosing schedules
Combination Therapies With cyclophosphamide, taxanes, vinorelbine, Abraxane
Novel Approaches Genetic-based dosing, low-dose for sepsis, sequential vs. concurrent administration
Key Outcomes Measured Pathological complete response, disease-free survival, overall survival, side effects
Biomarkers Explored Topoisomerase II alpha, HER-2, p53
Patient Populations Early-stage to advanced breast cancer, high-risk node-negative, node-positive

FAQ

  • What types of cancer is epirubicin being studied for in these clinical trials? Epirubicin is being studied in clinical trials for several types of cancer, including breast cancer, bladder cancer, and sepsis. The majority of the trials focus on its use in breast cancer treatment, both in early-stage and advanced cases.
  • How is epirubicin administered in these clinical trials? In the clinical trials, epirubicin is typically administered intravenously (IV). The dosing and frequency vary between trials, ranging from single doses to multiple cycles given every 2-3 weeks. Some trials are exploring different dosing strategies based on genetic factors or in combination with other drugs.
  • What are some potential side effects of epirubicin? Potential side effects of epirubicin mentioned in the trials include myelotoxicity (affecting blood cells), cardiotoxicity, nausea, vomiting, diarrhea, and hair loss. The trials are monitoring these side effects closely to ensure patient safety and to find ways to minimize them.
  • Are there any unique approaches being tested with epirubicin? Yes, some trials are exploring unique approaches with epirubicin. These include genetic-based dosing, combining epirubicin with newer drugs like Abraxane, and using it in sequential or concurrent regimens with other chemotherapy drugs. One trial is even studying a very low dose of epirubicin for treating sepsis.
  • What are researchers hoping to achieve with these epirubicin clinical trials? Researchers are aiming to improve treatment outcomes, reduce side effects, and find the most effective ways to use epirubicin. They are looking at factors that might predict which patients will respond best to the drug, exploring optimal dosing strategies, and investigating how epirubicin performs in combination with other treatments.

Ongoing Clinical Trials on Epirubicin

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Italy The Netherlands Spain

  • Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Ireland Spain

  • Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France Greece Ireland Italy Poland +1

  • Study on Nivolumab with Drug Combination for Patients with Intermediate Stage Liver Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria France Germany Hungary +3

  • Study on the Effectiveness of Carboplatin and Olaparib for Patients with Triple-Negative Breast Cancer with Positive HRD Status

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study on Adding Capecitabine to Carboplatin-Based Chemotherapy for Patients with Early Triple Negative Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Denmark Sweden

  • Study on the Effect of Tamoxifen and Chemotherapy in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with Low Recurrence Scores

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Epirubicin: A chemotherapy drug used to treat various types of cancer. It belongs to a class of drugs called anthracyclines and works by interfering with cancer cell DNA.
  • Neoadjuvant chemotherapy: Chemotherapy given before surgery to shrink tumors and make them easier to remove.
  • Adjuvant chemotherapy: Chemotherapy given after surgery to kill any remaining cancer cells and reduce the risk of cancer recurrence.
  • Pathological Complete Response (pCR): The absence of any detectable cancer in tissue samples after treatment, often used as a measure of treatment effectiveness.
  • Myelotoxicity: Toxicity to the bone marrow, which can result in decreased production of blood cells.
  • Cardiotoxicity: Toxicity that affects the heart, which can be a concern with some chemotherapy drugs.
  • Topoisomerase II alpha: An enzyme involved in DNA replication and a target for some chemotherapy drugs like epirubicin.
  • HER-2: A protein that promotes cancer cell growth and is overexpressed in some breast cancers.
  • FISH (Fluorescence In Situ Hybridization): A laboratory technique used to detect and locate specific DNA sequences on chromosomes.
  • Immunohistochemistry (IHC): A method of detecting specific proteins in tissues using antibodies.

References

  1. https://clinicaltrials.gov/study/NCT02225652
  2. https://clinicaltrials.gov/study/NCT00140075
  3. https://clinicaltrials.gov/study/NCT01740271
  4. https://clinicaltrials.gov/study/NCT01633203
  5. https://clinicaltrials.gov/study/NCT02214602
  6. https://clinicaltrials.gov/study/NCT00176488
  7. https://clinicaltrials.gov/study/NCT05033808